

THE LANCET

Rheumatology

Supplementary appendix

This appendix formed part of the original submission and has been peer reviewed.
We post it as supplied by the authors.

Supplement to: Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study. *Lancet Rheumatol* 2020; published online June 18. [https://doi.org/10.1016/S2665-9913\(20\)30169-7](https://doi.org/10.1016/S2665-9913(20)30169-7).

Appendix 1: Comparison between 47 COVID-19 positive patients admitted to hospital and 18 COVID-19 not hospitalized

	COVID-19 Admitted to hospital (n=47)	COVID-19 Not hospitalized (n=18)	P value, OR (95%CI)
Current age	70 (60.5-76.0)	54 (47.0-73.8)	0.036
Gender	29 (62) M 18 (38) F	12 (67) M 6 (33) F	0.71
Rheumatological Diagnosis, n (%)			
Rheumatoid Arthritis	16 (34)	8 (44)	0.43
Spondyloarthritis/Psoriatic Arthritis	7 (15)	3 (17)	1
Adult Onset Still's disease	3 (6)	0	0.55
Polymyalgia Rheumatica	3 (6)	1 (6)	1
Systemic Sclerosis	3 (6)	1 (6)	1
SLE (with or without APS)	3 (6)	3 (17)	0.33
Giant Cell Arteritis	2 (4)	0	1
Other vasculitis *	8 (17)	0	0.09
Other **	2 (4)	3 (17)	0.12
Rheumatological treatment, n (%)			
Glucocorticoids	31 (66)	12 (67)	0.95
Weekly dosage glucocorticoids (mg)	35 (25-50)	35 (21.3-35)	0.34
Colchicine	1 (2)	0	1
Conventional Synthetic DMARDs (csDMARDs)	28 (60)	12 (67)	0.59
Methotrexate	19 (40)	5 (28)	0.34
Hydroxychloroquine	5 (11)	5 (28)	0.12
Leflunomide	2 (4)	1 (6)	1
Azathioprine	1 (2)	1 (6)	0.48
Cyclosporine	1 (2)	1 (6)	0.48
Mycophenolate Mofetil	2 (4)	0	1
Sulfasalazine	0	1 (6)	0.27
Biological DMARDs (bDMARDs)	18 (38)	9 (50)	0.39
Infliximab	1 (2)	1 (6)	0.48
Etanercept	2 (4)	1 (6)	1
Adalimumab	7 (15)	1 (6)	0.42
Certolizumab pegol	1 (2)	1 (6)	0.48
Tocilizumab	1 (2)	2 (11)	0.18
Secukinumab	1 (2)	0	1
Anakinra	1 (2)	0	1
Belimumab	0	1 (6)	0.27
Abatacept	1 (2)	2 (11)	0.18
Previous/ongoing Rituximab	4 (9)	0	0.56
Apremilast	1 (2)	0	1
csDMARD+bDMARD	7 (15)	6 (33)	0.16
Comorbidities, n (%)			
Arterial Hypertension	27 (57)	6 (33)	0.082
Cardiovascular disease	5 (11)	3 (17)	0.67

Obesity (BMI>30)	10 (21)	1 (6)	0·26
Diabetes	8 (17)	1 (6)	0·42
Lung Disease***	7 (15)	0	0·17
Chronic Renal Insufficiency/ESRD	3 (6)	1 (6)	1
Cancer	0	2 (11)	0·074

Data are expressed as median (1st Quartile-3rd Quartile) or n (%). *Other vasculitis (i.e. Behçet Disease, polyarteritis nodosa, Takayasu's arteritis, eosinophilic granulomatosis with polyangiitis, cryoglobulinemia, Birdshot chorioretinopathy, other vasculitis), **Other (i.e. immune mediated myopathies, Sjögren's Syndrome, undifferentiated connective tissue disease, immunodeficiencies), ***Lung disease= asthma, chronic obstructive pulmonary disease, interstitial lung disease. Abbreviations: APS= antiphospholipid antibody syndrome; DMARDs= disease-modifying antirheumatic drugs; ESRD= end stage renal disorder; SLE= systemic lupus erythematosus.